5:28 PM
 | 
Sep 09, 2013
 |  BC Extra  |  Clinical News

Biodel falls on Phase II data for rapid-acting insulin

Biodel Inc. (NASDAQ:BIOD) fell $1.50 (30%) to $3.53 on Monday after reporting Phase II data for BIOD-123 that met the primary endpoint but raised questions about the commercial prospects of the ultra rapid-acting formulation of recombinant human insulin. BIOD-123 plus...

Read the full 188 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >